Compugen is Hunting down ‘Hot’ zone Targets for Immuno-Oncology

15/07/2016 - 2 minutes

Israel, we’re on our way! We leave Denmark with a smile and head down to sunny Tel-Aviv, where Compugen, a big Israeli-based leading drug discovery company and our Biotech of The Week, is located.

Compugen Biotech
Tel-Aviv (Israel)

Founded: 1993

Employees: 93 (as of 03/2016)

Financial Data: €257.2M Market Cap (on 22/03/2016)

CEO: Anat Cohen-Dayan

Related Content

Compugen Biotech cancer


Compugen-discovered drug targets are primarily immune checkpoint candidates that are predicted to provide cancer immunotherapies, both as monotherapy and in combinations. Although headquartered in Israel, it also has R&D facilities at its South San Francisco wholly-owned subsidiary.

With a focus on Immuno-Oncology, CGEN-15029 is the lead internal program in the Company’s pipeline. It is in fact is one of the multiple novel immune checkpoint target candidates discovered by the Company through the use of its unique in silico predictive discovery platforms.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member